Protein C3 Boosts Cancer Immunotherapy Efficacy in New Research
Stanford researchers discovered that a protein called C3, which evolved before the human circulatory system, can enhance cancer immunotherapy by blocking immune-suppressing cells. The finding may unlock stronger treatments for multiple cancer types.
Ancient Protein Becomes Cancer Fighter
A protein that evolved long before the human circulatory system may help unlock stronger cancer treatments. When C3 is produced inside tumors, it blocks immune-suppressing cells and gives immunotherapy a better chance to work. This discovery reveals how evolutionary biology can inform modern cancer therapeutics.
The Complement System Connection
C3 is a key component of the complement system, an ancient branch of the innate immune system that predates vertebrate adaptive immunity. Normally, complement functions to tag pathogens for destruction and activate immune cells. Stanford researchers identified that within the tumor microenvironment, C3 can disrupt the recruitment or function of regulatory T cells and myeloid-derived suppressor cells—immune populations that typically protect tumors from attack.
Overcoming Tumor Immune Evasion
Many cancers survive by recruiting "off" switches in the immune system. Checkpoint inhibitors like anti-PD-1 and anti-CTLA-4 antibodies work by releasing these brakes. The C3 discovery suggests a complementary approach: by activating complement directly within tumors, researchers may prime the microenvironment for more effective immunotherapy. The combination could overcome resistance mechanisms that allow some patients' tumors to evade single-agent checkpoint inhibitor therapy.
Clinical Development Path
Researchers were even able to design strategies to harness C3 in preclinical models. The next phase involves translating this work to animal models and eventually clinical trials. If successful, C3-based approaches could be tested alone or in combination with existing checkpoint inhibitors, potentially expanding treatment options for immunotherapy-resistant cancers.
Broader Implications
This research exemplifies how understanding ancient immune mechanisms can unlock new therapeutic strategies. Complement-based approaches are being explored across multiple cancer types, and C3 may represent a foundational target for combination immunotherapy.